Indeed, BCR-ABL-positive CML and EGFR mutation-positive non-small cell lung cancer (NSCLC) cells expressing BIM-γ exhibit resistance to imatinib and gefitinib (EGFR TKI), respectively [124]. This evidence concerns the gene ABL1 and non-small cell lung carcinoma.